Virtual reality-assisted rehabilitation after arthroscopic rotator cuff repair for small-to-medium supraspinatus tears: a prospective assessor-blinded randomized controlled trial
- 1Department of Orthopedic Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, PR China
- 2Department of Sports Medicine, Binhai Campus of the First Affiliated Hospital, National Regional Medical Center, Fujian Medical University, Fuzhou, PR China
- 3Fujian Orthopaedics Research Institute, Fuzhou, PR China
Abstract
Background: Rehabilitation after arthroscopic rotator cuff repair (ARCR) must protect the repair while restoring active shoulder use. Immersive virtual reality (VR) can standardize rehabilitation tasks and provide immediate feedback, but whether VR delivery offers benefit over conventional delivery when exercise dose and therapist supervision are matched remains uncertain.
Methods: This assessor-blinded randomized trial assigned 86 adults undergoing ARCR for small-to-medium full-thickness supraspinatus tears 1:1 to VR-assisted or conventional rehabilitation. During postoperative weeks 4–8, both groups received matched exercise content, dose, progression criteria, safety limits, and face-to-face therapist supervision; only the delivery format differed. Assessments were conducted at baseline, weeks 4 and 6, and months 2, 3, and 6. The primary outcome was activity-related pain measured using a 10-cm visual analogue scale (VAS). Secondary outcomes included rest pain, the 17-item Tampa Scale for Kinesiophobia (TSK-17), Constant-Murley Score (CMS), global shoulder active range of motion, the 12-item Short Form Health Survey (SF-12), isometric strength, and supraspinatus cross-sectional area; surface electromyography (sEMG) was exploratory. Complete-case longitudinal outcomes were analysed using repeated-measures analysis of variance.
Results: Seventy participants completed all assessments (VR, n = 36; conventional rehabilitation, n = 34); mean age was 58.1 years, 47 (67.1%) were women, and 35 (50.0%) had small tears. Baseline activity-related VAS scores were 7.3 and 7.2 cm, and mean CMS values were 49.2 and 48.7 in the VR and conventional rehabilitation groups, respectively. Mean activity-related pain was 0.7 cm lower with VR at 6 weeks (4.0 vs. 4.7) and 0.8 cm lower at 2 months (3.1 vs. 3.9); both differences were smaller than the published 1.4-cm clinical-importance threshold. The TSK-17 group × time interaction was significant (P = 0.001); at 3 months, the mean difference was − 3.1 points (95% CI − 4.5 to − 1.8; Hedges g = − 1.11). Rest pain was similar between groups, and group × time interactions for CMS, global shoulder active range of motion, SF-12, isometric strength, supraspinatus cross-sectional area, and exploratory sEMG outcomes were nonsignificant. No clear between-group difference in activity-related pain or TSK-17 was apparent at 6 months.
Conclusions: In the complete-case analysis, VR delivery was associated with lower activity-related pain at 6 weeks and 2 months and lower TSK-17 scores at 3 months compared with conventional rehabilitation. The pain differences were below a published clinical-importance threshold, and the clinical importance of the TSK-17 difference remains uncertain. No between-group difference in activity-related pain or TSK-17 was apparent at 6 months, and the trial did not demonstrate broader functional, structural, or neuromuscular benefits.
Trial registration: Chinese Clinical Trial Registry (https://www.chictr.org.cn), ChiCTR2400088194. Registered 13 August 2024. Recruitment began on 14 August 2024, after registration.
Related
- Effect of Hand Grip Exercise on Rotator Cuff Strength and Shoulder Function Recovery after Arthroscopic Rotator Cuff Repair: A Prospective Randomized Controlled Trial
- Integrated rehabilitation for post-stroke anxiety: a prospective, multicenter, randomized controlled trial
- Efficacy of a smartphone digital therapeutic (re-R) for post-total knee arthroplasty rehabilitation: study protocol for a single-center randomized controlled trial in the Republic of Korea
- Exploring sex-dependent responses to anodal tDCS in subacute stroke rehabilitation: a post-hoc analysis of the randomized sham-controlled NETS Trial
- Feasibility, Safety, and Preliminary Efficacy of Partnered Rhythmic Rehabilitation in Prodromal Alzheimer's Disease: A 12-Month Pilot Randomized Controlled Trial
BibTeX
@article{wu2026virtual,
title = {{Virtual reality-assisted rehabilitation after arthroscopic rotator cuff repair for small-to-medium supraspinatus tears: a prospective assessor-blinded randomized controlled trial}},
author = {Song-ye Wu and Liang Chen and Yan-song Zhu and Jian-ning Sun and Peng Chen},
journal = {BMC Musculoskeletal Disorders},
year = {2026},
month = aug,
doi = {10.1186/s12891-026-10326-w},
url = {https://doi.org/10.1186/s12891-026-10326-w},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Virtual reality-assisted rehabilitation after arthroscopic rotator cuff repair for small-to-medium supraspinatus tears: a prospective assessor-blinded randomized controlled trial
AU - Song-ye Wu
AU - Liang Chen
AU - Yan-song Zhu
AU - Jian-ning Sun
AU - Peng Chen
PY - 2026
DA - 2026/08/07
JO - BMC Musculoskeletal Disorders
DO - 10.1186/s12891-026-10326-w
UR - https://doi.org/10.1186/s12891-026-10326-w
AB - Background: Rehabilitation after arthroscopic rotator cuff repair (ARCR) must protect the repair while restoring active shoulder use. Immersive virtual reality (VR) can standardize rehabilitation tasks and provide immediate feedback, but whether VR delivery offers benefit over conventional delivery when exercise dose and therapist supervision are matched remains uncertain. Methods: This assessor-blinded randomized trial assigned 86 adults undergoing ARCR for small-to-medium full-thickness supraspinatus tears 1:1 to VR-assisted or conventional rehabilitation. During postoperative weeks 4–8, both groups received matched exercise content, dose, progression criteria, safety limits, and face-to-face therapist supervision; only the delivery format differed. Assessments were conducted at baseline, weeks 4 and 6, and months 2, 3, and 6. The primary outcome was activity-related pain measured using a 10-cm visual analogue scale (VAS). Secondary outcomes included rest pain, the 17-item Tampa Scale for Kinesiophobia (TSK-17), Constant-Murley Score (CMS), global shoulder active range of motion, the 12-item Short Form Health Survey (SF-12), isometric strength, and supraspinatus cross-sectional area; surface electromyography (sEMG) was exploratory. Complete-case longitudinal outcomes were analysed using repeated-measures analysis of variance. Results: Seventy participants completed all assessments (VR, n = 36; conventional rehabilitation, n = 34); mean age was 58.1 years, 47 (67.1%) were women, and 35 (50.0%) had small tears. Baseline activity-related VAS scores were 7.3 and 7.2 cm, and mean CMS values were 49.2 and 48.7 in the VR and conventional rehabilitation groups, respectively. Mean activity-related pain was 0.7 cm lower with VR at 6 weeks (4.0 vs. 4.7) and 0.8 cm lower at 2 months (3.1 vs. 3.9); both differences were smaller than the published 1.4-cm clinical-importance threshold. The TSK-17 group × time interaction was significant (P = 0.001); at 3 months, the mean difference was − 3.1 points (95% CI − 4.5 to − 1.8; Hedges g = − 1.11). Rest pain was similar between groups, and group × time interactions for CMS, global shoulder active range of motion, SF-12, isometric strength, supraspinatus cross-sectional area, and exploratory sEMG outcomes were nonsignificant. No clear between-group difference in activity-related pain or TSK-17 was apparent at 6 months. Conclusions: In the complete-case analysis, VR delivery was associated with lower activity-related pain at 6 weeks and 2 months and lower TSK-17 scores at 3 months compared with conventional rehabilitation. The pain differences were below a published clinical-importance threshold, and the clinical importance of the TSK-17 difference remains uncertain. No between-group difference in activity-related pain or TSK-17 was apparent at 6 months, and the trial did not demonstrate broader functional, structural, or neuromuscular benefits. Trial registration: Chinese Clinical Trial Registry (https://www.chictr.org.cn), ChiCTR2400088194. Registered 13 August 2024. Recruitment began on 14 August 2024, after registration.
SN - 1471-2474
ER -